However, the later published evidence that the two breast cancer CSC populations (i.e., ALDH+ and CD24−/CD44+) investigated reside in different areas of primary breast tumors and can transition from one phenotype to the other (19) might affect the reliability of CSC counts in this patient population. The gene discussed is CD44; the disease is breast carcinoma.